These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23992693)

  • 1. Invited commentary.
    Antonoff MB
    Ann Thorac Surg; 2013 Sep; 96(3):968. PubMed ID: 23992693
    [No Abstract]   [Full Text] [Related]  

  • 2. EGFR: a prognostic and/or a predictive marker?
    Hirsch FR
    J Thorac Oncol; 2006 Jun; 1(5):395-7. PubMed ID: 17409888
    [No Abstract]   [Full Text] [Related]  

  • 3. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Costa DB; Kobayashi S
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular signatures of lung cancer--toward personalized therapy.
    Herbst RS; Lippman SM
    N Engl J Med; 2007 Jan; 356(1):76-8. PubMed ID: 17202459
    [No Abstract]   [Full Text] [Related]  

  • 5. A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?
    Kaye FJ
    J Natl Cancer Inst; 2005 May; 97(9):621-3. PubMed ID: 15870427
    [No Abstract]   [Full Text] [Related]  

  • 6. Highlights in NSCLC from the 2014 ASCO meeting.
    Socinski MA
    Clin Adv Hematol Oncol; 2014 Oct; 12(10 Suppl 18):16-9. PubMed ID: 25768033
    [No Abstract]   [Full Text] [Related]  

  • 7. Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.
    Yu XM; Wu YC; Liu X; Huang XC; Hou XX; Wang JL; Cheng XL; Mao WM; Ling ZQ
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invited commentary.
    Lee HS; Zo JI
    Ann Thorac Surg; 2012 May; 93(5):1613. PubMed ID: 22541191
    [No Abstract]   [Full Text] [Related]  

  • 9. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.
    Shepherd FA; Tsao MS
    J Clin Oncol; 2006 Mar; 24(7):1219-20; author reply 1220-1. PubMed ID: 16505443
    [No Abstract]   [Full Text] [Related]  

  • 10. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
    Haddad FG; Kourie HR; Kattan J
    Future Oncol; 2017 Feb; 13(3):201-204. PubMed ID: 27624407
    [No Abstract]   [Full Text] [Related]  

  • 12. Pitfalls in the assessment of prognostic factors.
    Metze K
    Lancet Oncol; 2011 Nov; 12(12):1095-6. PubMed ID: 22041541
    [No Abstract]   [Full Text] [Related]  

  • 13. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing EGFR mutations.
    Marchetti A; Felicioni L; Buttitta F
    N Engl J Med; 2006 Feb; 354(5):526-8; author reply 526-8. PubMed ID: 16452569
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invited commentary.
    Antonoff MB
    Ann Thorac Surg; 2015 May; 99(5):1754. PubMed ID: 25952203
    [No Abstract]   [Full Text] [Related]  

  • 17. Are all KRAS mutations created equal?
    Stinchcombe TE; Der CJ
    Lancet Oncol; 2011 Aug; 12(8):717-8. PubMed ID: 21782508
    [No Abstract]   [Full Text] [Related]  

  • 18. Validation of a reverse transcription-polymerase chain reaction-based five-gene signature in non-small cell lung cancer.
    Ruco L; Scarpino S; Natoli G
    J Thorac Oncol; 2009 May; 4(5):670. PubMed ID: 19395916
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.
    Yang SL; Ren QG; Wen L; Hu JL
    J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):321-327. PubMed ID: 27376798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.